Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
GlucoTrack, Inc. develops medical technology for people with diabetes, centered on a long-term, fully implantable continuous blood glucose monitoring system. Company news commonly covers the CBGM platform, FDA Investigational Device Exemption activity, preclinical and clinical-study disclosures, and peer-reviewed publications on sensor stability, accuracy, and implantable device performance.
Updates also include intellectual-property developments for proprietary sensor chemistry, intravascular lead design, and low-power electronics, along with financial results, research and development spending, capital actions, and conference presentations tied to the company’s diabetes device strategy.
GlucoTrack, Inc. (Nasdaq: GCTK), previously known as Integrity Applications, Inc. (Nasdaq: IGAP), has officially changed its corporate name and ticker symbol as of March 14, 2022. This transition reflects the company's focus on non-invasive glucose monitoring technologies for Type 2 diabetes and prediabetes. The name and symbol changes do not affect stockholder rights or outstanding shares. Shareholders holding physical certificates will receive instructions for exchanging them. GlucoTrack’s device aims to provide a pain-free alternative to traditional glucose monitoring methods.